| |
- Structural normalization of the lymphoid tissue asymptomatic HIV-infected patients after 48 weeks potent antiretroviral therapy
(12/28/01)
- Transmission of zidovudine resistant strains of HIV-1: the first wave Written by Sally Blower
(12/27/01)
- Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users
(12/27/01)
- The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women
(12/27/01)
- Long-term efficacy of combination therapy with interferon-2b and ribavirin for severe chronic hepatitis C in HIV-infected patients
(12/27/01)
- Acute HIV infection: impact on the spread of HIV and transmission of drug resistance
(12/27/01)
- Effect of adherence to newly initiated antiretroviral therapy on plasma viral load
(12/27/01)
- High prevalence of HIV infection among youth in a South African mining town is associated with HSV-2 seropositivity and sexual behaviour
(12/27/01)
- Increased STDs & HIV Transmission; HCV/HIV Coinfection ../IDSA San Francisco, CA(12/27/01)
- New HIV drugs, resistance, pharmacogenomicsWritten by Mike Youle, Director of HIV at Royal Free Hospital, UK, London (12/27/01)
- Drug Interactions and Pharmacokinetics of AntiretroviralsStephen Piscitelli, Pharm.D. Associate Director, Clinical Pharmacology Tibotec-Virco(12/27/01)
- Safety and Efficacy of Tipranavir (TPV), a Novel Non-Peptide Protease Inhibitor Written by Jules Levin (12/27/01)
- Anitiretroviral Agents: adherence, PKWritten by Scott Penzak, PharmD, National Institutes of Health (12/27/01)
- Pharmacokinetic Issues of AntiretroviralsWritten by Stephen Piscitelli, Pharm.D. Associate Director, Clinical Pharmacology Tibotec-Virco (12/27/01)
- Antiretroviral Therapy: Part 2.- FTC, Interferon, TMC-114 (new PI) Reported for NATAP by Grame Moyle, MD, Ass. Dir. of HIV Research at Chelsea &
Westminster Hospital, UK, London(12/27/01)
- Kaletra and Amprenavir Interaction Two Reports: Impact of ABT 378/r (Kaletra) on the amprenavir (APV) plasma concentrations in HIV-experienced patients treated by the association APV-ABT 378/r by Scott Penzak, PharmD, NIH - and- APV + Kaletra: Is there an interaction here? by Written by Steve Piscatelli, PharmD, Tibotec-Virco (12/27/01)
- ddI-Tenofovir interaction; ddI-Ribavirin-Interferon interaction; 3TC-ribavirin interaction; elevated glucose & diabetes in HCV/HIV coinfected patients Written for NATAP by Stephen Piscitelli, Pharm.D., Associate Director, Clinical Pharmacology, Tibotec-Virco and Jules Levin, NATAP (12/27/01)
- The Prevalence of Antiretroviral Drug Resistance in the US(12/27/01)
- Psychological Aspects of Living with HIV Disease
(12/21/01)
- Antiviral PK and Drug-Drug Interactions, Report #1 Reported for NATAP by Scott Penzak, PhD, National Institutes of Health (NIH)
(../ICAAC) Chicago,Illinois
(12/21/01)
- NATAP ../ICAAC 2001 Antiretroviral therapy, Part 1 Dr Graeme Moyle, Chelsea and Westminster Hospital, London, UK.
(../ICAAC) Chicago,Illinois
(12/21/01)
- Solid Organ Transplantation in Patients with Human Immunodeficiency Syndrome: a Successful Case Series.
(../ICAAC) Chicago,Illinois
(12/21/01)
- TMC125 is a Highly Potent Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in Antiretroviral Therapy (ART)-Naive, HIV-1 Infected Subjects
(../ICAAC) Chicago,Illinois
(12/21/01)
- Tenofovir 24 week Interim Analysis Phase III Trial in Treatment-Experienced Patients
(../ICAAC) Chicago,Illinois
(12/19/01)
- BMS-008 Comparative Results of Atazanavir vs Nelfinavir in Combination With d4T (Stavudine) and 3TC (Lamivudine) in treatment-Naive, HIV-Infected Patients
(../ICAAC) Chicago,Illinois
(12/19/01)
- Once-Daily Atazanavir plus Saquinavir Favorably Affects Total Cholesterol and Fasting Triglycerides in patients Failing Prior PI Therapy Study BMS-009, week 24)
(../ICAAC) Chicago,Illinois
(12/19/01)
- Fat Loss: efavirenz + AZT/3TC vs indinavir AZT/3TC in study 006 - (12/17/01)
- Is the Natural History of Hepatitis C Virus Carriers With Normal Aminotransferase Really Benign?
(12/17/01)
- Amprenavir (APV) Plasma and Intracellular Concentrations When Co-Administered with Ritonavir (RTV) in Twice and Once Daily Regimens in HIV-Infected Patients
(../ICAAC) Chicago,Illinois
(12/17/01)
- Evaluation of Two doses of Peginterferon Alfa-2a (40KD) (Pegasys) for the Treatment of Chronic Hepatitis C
(../ICAAC) Chicago,Illinois
(12/17/01)
- The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study PDF
(12/10/01)
- FIBROSIS (F) AND HISTOLOGICAL ACTIVITY INDEX (HAI) IMPROVE SPONTANEOUSLY IN UNTREATED, NONCIRRHOTIC, PERSISTENTLY VIREMIC IRISH WOMEN WITH CHRONIC HEPATITIS C.
(AASLD) Dallas, Texas
(12/4/01)
- PREDICTIVE VARIABLES OF HCV-RELATED DISEASE PROGRESSION: NEGATIVE EFFECT OF OVERWEIGHT: diabetes, ALT >60, and weight can have an effect on HCV progression
(AASLD) Dallas, Texas
(12/4/01)
- INFLUENCE OF STEATOSIS ON CHRONIC HEPATITIS C OUTCOME: PROSPECTIVE STUDY OF 164 PATIENTS WITH CIRRHOSIS
(AASLD) Dallas, Texas
(12/4/01)
- TIMING THE ANCESTRY OF HEPATITIS C VIRUS GENOTYPE 1A STRAINS IN THE UNITED STATES: the number of mutations don't seem to be associated with disease progression
(AASLD) Dallas, Texas
(12/4/01)
- One A Day Regimen for HIV: pilot study of FTC, ddI, efavirenz (ECCATHI), Athens, Greece
(12/3/01)
- IMPACT OF PREGNANCIES, ORAL CONTRACEPTION AND MENOPAUSE ON LIVER FIBROSIS PROGRESSION IN WOMEN WITH CHRONIC HEPATITIS C
(AASLD) Dallas, Texas
(12/3/01)
- CLINICAL IMPLICATIONS OF A NEW TRI-PHASIC MODEL FOR HEPATITIS C VIRAL KINETICS DURING IFN-a THERAPY
(AASLD) Dallas, Texas
(12/3/01)
- LIPID ABNORMALITIES AND CARDIOVASCULAR RISK Written for NATAP by Michael Dube, MD, University of Indiana and the ACTG - Report - (../../lipodystrophy Conf) Athens, Greece
(12/03/01)
|
